GENE ONLINE|News &
Opinion
Blog

2021-10-08| Special

Landmark CRISPR Trial Shows Promise Against Fighting Blindness, but Is It a Cure?

by Isha Kapoor
Share To
Cambridge, MA-based, leading genome editing biotech company, Editas Medicine, recently announced encouraging clinical data in the world's first attempt to use the CRISPR gene editing tool to treat blindness.

Preliminary results from the open-label Phase1/2 BRILLIANCE clinical trial of its investigational CRISPR-based experimental medicine, EDIT-101, have rekindled hope for the patients suffering from blindness due to Leber congenital amaurosis 10 (LCA10).

The safety and efficacy assessments were presented at the XIXth International Symposium on Retinal Degeneration (RD2021) on September 29th.

GO Prime with only $1.49 now

LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!